aTyr Pharma (@aTyrNews) / X

aTyr Pharma

1,088 posts

aTyr Pharma

@aTyrNews

aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways.

San Diego, CA

Joined March 2011

aTyr Pharma
@aTyrNews
Jul 22, 2025
Today we announced that the last patient has completed their last visit in our Phase 3 EFZO-FIT™ study of efzofitimod in patients with #pulmonarysarcoidosis. We look forward to sharing topline results later this quarter. Read more: bit.ly/4f5DnW4
5.4K
aTyr Pharma
@aTyrNews
Sep 13, 2021
aTyr Pharma is pleased to announce positive data from our Phase 1b/2a clinical trial of ATYR1923 in Pulmonary Sarcoidosis patients. For more information, please click the link below: bit.ly/3A9t7GX $LIFE #ATYR1923
aTyr Pharma
@aTyrNews
Aug 11, 2022
Today we announced that the U.S. FDA has granted Fast Track designation for efzofitimod for the treatment of pulmonary sarcoidosis. This designation for efzofitimod underscores the need for a new therapy for patients living w/ pulmonary sarcoidosis. More: bit.ly/3PeQMfN
aTyr Pharma
@aTyrNews
Jul 11, 2022
Listen as aTyr’s President and CEO, Dr. Sanjay S. Shukla, speaks with John Carlin, @StopSarcoidosis advocate and host of the Sarc Fighter podcast, in Episode 65 about the upcoming Phase 3 study of efzofitimod in patients with pulmonary sarcoidosis. bit.ly/2PXOitM
aTyr Pharma
@aTyrNews
Jul 22, 2024
Today we announced that we have completed enrollment in the global pivotal Phase 3 EFZO-FIT™ study of #efzofitimod in patients with #pulmonarysarcoidosis, a major form of #ILD. Topline data are expected in the third quarter of 2025. For more information: bit.ly/3YeM1vc
2.4K
aTyr Pharma
@aTyrNews
Jun 4, 2025
Today we announced findings from an interim analysis of skin assessments for 8 patients at 12 weeks in our ongoing Phase 2 EFZO-CONNECT™ study of efzofitimod in limited or diffuse SSc-ILD. Read more here: bit.ly/4mHqAg5
2.9K
aTyr Pharma
@aTyrNews
Apr 12, 2022
DYK: More than 90% of people diagnosed with sarcoidosis will have lung involvement, which is known as #pulmonarysarcoidosis. Common symptoms of pulmonary sarcoidosis include cough, chest pain, wheezing and shortness of breath. #stopsarc #makeitvisible #Efzofitimod $LIFE
aTyr Pharma
@aTyrNews
May 19, 2025
Today we announced three poster presentations for efzofitimod at #ATS2025. Join us in person at the poster presentations or view the posters on our website once presented. Read more here: bit.ly/45kmpAn $ATYR
1.9K
aTyr Pharma
@aTyrNews
Jul 22, 2022
Current treatment for #sarcoidosis are limited & typically include using corticosteroids to control inflammation and manage symptoms, such as cough and shortness of breath for patients w/ pulmonary sarcoidosis. aTyr is developing efzofitimod. More: bit.ly/3OrarJd
aTyr Pharma
@aTyrNews
May 14, 2025
Today we announced that we have advanced ATYR0101 to IND candidate stage for #pulmonaryfibrosis. ATYR0101 and its novel anti-fibrotic mechanism was selected to be showcased at the #ATS2025 Respiratory Innovation Summit May 16-17 in San Francisco. bit.ly/43hnneg
814
aTyr Pharma
@aTyrNews
Sep 27, 2022
We are pleased to announce that we have dosed the first patient in EFZO-FIT™, a global pivotal Phase 3 study to evaluate the efficacy and safety of efzofitimod in patients with pulmonary sarcoidosis. Learn more here: bit.ly/3LO0x4t #pulmonarysarcoidosis $LIFE
aTyr Pharma
@aTyrNews
Jun 26, 2025
Today we announced that $ATYR is expected to be added to the Russell 2000® Index and broad market Russell 3000® Index, effective after the U.S. market close on June 27, 2025, as part of the 2025 Russell U.S. Indexes annual reconstitution. Read more: bit.ly/4eibw4q
2.2K
aTyr Pharma
@aTyrNews
Sep 9, 2021
Sarcoidosis can affect any organ in the body, and 90% or more of patients with sarcoidosis will have lung involvement ATYR1923 is working to improve outcomes in those affected by Pulmonary Sarcoidosis. More here: zcu.io/hcMi #ATYR1923 #PulmonarySarcoidosis $LIFE
aTyr Pharma
@aTyrNews
Aug 7, 2025
We released our Second Quarter 2025 financial results and corporate update today. To read the full earnings press release, click here: bit.ly/4mwLqh0 $ATYR
7K